These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30177490)

  • 1. Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease.
    Cheng YQ; Ge NN; Zhu HH; Sha ZT; Jiang T; Zhang YD; Tian YY
    Parkinsonism Relat Disord; 2019 Jan; 58():70-73. PubMed ID: 30177490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.
    Mestre TA; Freitas E; Basndwah A; Lopez MR; de Oliveira LM; Al-Shorafat DM; Zhang T; Lui JP; Grimes D; Fox SH
    Mov Disord; 2020 Dec; 35(12):2319-2323. PubMed ID: 32657457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.
    Thomsen TR; Galpern WR; Asante A; Arenovich T; Fox SH
    Mov Disord; 2007 Nov; 22(15):2268-73. PubMed ID: 17876852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial.
    Arbouw ME; Movig KL; Koopmann M; Poels PJ; Guchelaar HJ; Egberts TC; Neef C; van Vugt JP
    Neurology; 2010 Apr; 74(15):1203-7. PubMed ID: 20385892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease.
    Perez Lloret S; Pirán Arce G; Rossi M; Caivano Nemet ML; Salsamendi P; Merello M
    Mov Disord; 2007 Jan; 22(1):107-11. PubMed ID: 17089393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis.
    Yang CL; Huang JP; Tan YC; Wang TT; Zhang H; Qu Y
    BMC Pharmacol Toxicol; 2023 Oct; 24(1):52. PubMed ID: 37828600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialorrhea in Parkinson's disease: a review.
    Chou KL; Evatt M; Hinson V; Kompoliti K
    Mov Disord; 2007 Dec; 22(16):2306-13. PubMed ID: 17659637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialorrhea in Parkinson's Disease.
    Isaacson J; Patel S; Torres-Yaghi Y; Pagán F
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33142833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin for treatment of parkinsonian sialorrhea.
    Friedman A; Potulska A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():23-7. PubMed ID: 12001650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
    Lloret SP; Nano G; Carrosella A; Gamzu E; Merello M
    J Neurol Sci; 2011 Nov; 310(1-2):248-50. PubMed ID: 21636098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson's disease: a systematic review and network meta-analysis.
    Santos Junior LC; Santos JR; Reis A; Faria-E-Silva AL; Leal PC
    Clin Oral Investig; 2023 Jun; 27(6):2449-2463. PubMed ID: 37036514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum Toxin Therapy for Parkinson's Disease.
    Wagle Shukla A; Malaty IA
    Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease.
    Farber NM; Perez-Lloret S; Gamzu ER
    Curr Top Med Chem; 2015; 15(10):939-54. PubMed ID: 25832720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.